About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Scientists Running Your Drug Company? | Main | Pfizer's New Structure: Good Luck To All »

April 7, 2009

Biogen Idec: What's Going On?

Email This Entry

Posted by Derek

Biogen Idec has continued to fight off Carl Icahn, opposing his nominees to the company's board and setting up a fight at the annual meeting later this year.

But this morning (as a correspondent has just pointed out to me) the company's stock has been taking off. It's up about 7%, with the broad market down, and all of this rise seems to have been since 11 AM. Someone's stepping up and buying a good amount of BIIB, for some reason. But who, and why?

Update: ah, here we go - rumors of Sanofi-Aventis or some other non-Ichan entity stepping in. We'll see if there's anything to it. . .

Comments (7) + TrackBacks (0) | Category: Business and Markets | Current Events


1. Bob on April 7, 2009 12:14 PM writes...

The company itself? Icahn? And remember the stock has taken a hit the last few days. It is undervalued for a long time anyway, and its earnings are due out soon, and look to be better than expected.

Permalink to Comment

2. Hap on April 7, 2009 12:25 PM writes...

Could it be normal variation? This link seems to indicate that there are a fair number of days in the last six months where the stock price has gone up or down by up to 10%, so it might just be their stockholders. I don't know how it is paid, but their dividend might be today, too.

If something interesting happens soon, I'm sure the SEC will be interested in the activity, though.

Permalink to Comment

3. Petros on April 7, 2009 2:30 PM writes...

Well sanofiaventis eems to be feeling acquisitive. It's picked up the Mexican generic comnay Kendrick, is rumoured to be buying the Brazilian firm Medley and in talks with Solvay for the latter's pharma business.

Permalink to Comment

4. Furd on April 7, 2009 2:41 PM writes...

Dividend ? Obviously you follow Biogen religiously.

Permalink to Comment

5. china.bonding on April 7, 2009 9:59 PM writes...

yes, sanofi seems hungry. I wonder if Amgen is a dark horse, too?
Circle the wagons on biotech P/E ratios or get gobbled up.

Permalink to Comment

6. Chuck Kettler on April 8, 2009 6:55 AM writes...

Anybody who has had the opportunity to tour the BiogenIdec manufacturing facilities can tell you they are far ahead of the majority in process understanding and control of building and isolating large molecules. Their multivariate trajectory modeling gives them an advantage that most companies cannot fathom because they hesitate to make the infrastructure capital commitments. Lots to learn from those folks, but probably not on our radar.

Permalink to Comment

7. Edwin Giron on April 8, 2009 12:26 PM writes...

There's always some turbulence when Carl Icahn gets involved. From personal experience, his ambitions with Mylan (MYL), led to the demise of Bertek Pharmaceuticals. I hope the same doesn't happen with Biogen.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry